We want to find better ways to support people suffering with mental health challenges, and we believe we’re onto something important.
Healthy volunteers study
As part of our psilocybin therapy development programme, we partnered with the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London to run a study with healthy volunteers. The study was a phase I, double-blind placebo-controlled study with 89 healthy volunteers, aged between 18 and 65 years.
The study demonstrated the feasibility of administering COMP360 psilocybin to up to six healthy participants simultaneously, with 1:1 support. There were no serious adverse events and COMP360 psilocybin was found to be well-tolerated with no clinically-relevant negative effects on cognitive function.
The study was presented at the ACNP 2019 annual meeting (see poster), and at the ASCP 2021 annual meeting (see poster), and published in the peer-reviewed Journal of Psychopharmacology in 2022 (see paper and our press release).
Hear Dr James Rucker talking about this study
Poster presented at the 58th Annual Meeting of The American College of Neuropsychopharmacology, December 2019
Virtual poster presented at the American Society of Clinical Psychopharmacology Annual Meeting, June 2021
Study published in Journal of Psychopharmacology, January 2022
In November 2021, we announced data from our phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression.